SCHEMBL22019774

SCHEMBL22019774

Cc1c2c(nc3c1CC(C)C3)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
BPTF Q12830 1/20 0.39
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 2/20 0.39
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
CYP1A2 P05177 1/20 0.33
GAA P10253 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
USP2 O75604 1/20 0.33
MAPT P10636 3/20 0.33
NPC1 O15118 2/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
OPRK1 P41145 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19272311 0.82 ACHE (0.54) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL22020300 0.80 ACHE (0.62) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL22021532 0.80 ACHE (0.58) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL22019719 0.77 USP2 (0.37) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL22021004 0.77 NPSR1 (0.37) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL12507661 0.77 ACHE (0.56) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL22019718 0.69 HRH3 (0.38) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL22020826 0.69 HRH3 (0.38) ACHEMEN1MAPK1KMT2ABPTF
SCHEMBL22021272 0.69 HRH3 (0.38) ACHEMEN1MAPK1KMT2ABPTF
Hydrochloric Acid SCHEMBL31647683 0.67 KDM4E (0.41) ACHEMEN1MAPK1KMT2ABPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020154499-A1 SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-07-30 WO disclosed
WO-2020102096-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed